Skip to main content
OpenTrials
Completed

NCT Number: NCT00753285

Renal Denervation in Patients With Refractory Hypertension

The purpose of this study is to investigate the clinical utility of renal denervation for the treatment of refractory hypertension.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Prairie Heart Institute, Springfield, Illinois, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Systolic blood pressure of 160 mmHg or greater
  • On 3 or more antihypertensive medications
  • eGFR >= 45 mL/min

Exclusion criteria

  • Renal artery abnormalities
  • Known secondary hypertension attributable to a cause other than sleep apnea
  • MI, angina, CVA within 6 months
  • Type 1 diabetes
  • Others

Treatment and study plan

Renal Denervation

Device

Other names: Symplicity Renal Denervation System

Primary outcomes

  1. Safety - complications associated with delivery and/or use of the Ardian Catheter, adverse renal events, electrolyte disturbances, hemodynamic events.

    Time frame: Through 3 years

Secondary outcomes

  1. Physiologic response to renal denervation (e.g., blood pressure reduction)

    Time frame: Through 3 years

Sponsors and collaborators

Lead sponsor

Medtronic Vascular

Industry

Registry information

Important dates

Study start
2008
Primary completion
2013
Study completion
2013
First posted
Sep 16, 2008
Registry last updated
Nov 10, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.